Table 4B.
Univariable and multivariable analysis of predictors of mortality in the CLL patients.
| CLL | ||||||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | |||||||
| p value | HR | 95% CI | p value | HR | 95% CI | |||
| Lower | Upper | Lower | Upper | |||||
| Sex | ||||||||
| Female | - | - | - | - | ||||
| Male | 0.381 | 1.262 | 0.750 | 2.124 | ||||
| Age | 0.010 | 1.031 | 1.008 | 1.056 | 0.002 | 1.040 | 1.015 | 1.066 |
| Status malignancy at COVID-19 diagnosis | ||||||||
| Controlled malignancy | - | - | - | - | ||||
| Stable malignancy | 0.977 | 1.009 | 0.548 | 1.859 | ||||
| Active malignancy | 0.146 | 1.594 | 0.850 | 2.989 | ||||
| Malignancy | ||||||||
| Chronic lymphoid leukemia | ||||||||
| Non-Hodgkin lymphoma | ||||||||
| COVID-19 infection | ||||||||
| Asymtomatic | - | - | - | - | - | - | - | - |
| Mild | 0.911 | 0.913 | 0.184 | 4.523 | 0.988 | 0.988 | 0.199 | 4.897 |
| Severe | 0.057 | 3.162 | 0.964 | 10.366 | 0.053 | 3.227 | 0.984 | 10.582 |
| Critical | 0.001 | 7.090 | 2.170 | 23.162 | <0.001 | 8.251 | 2.516 | 27.062 |
| Chronic cardiopathy | 0.081 | 1.532 | 0.949 | 2.472 | 0.480 | 1.200 | 0.723 | 1.991 |
| Chronic pulmonary disease | 0.435 | 1.235 | 0.728 | 2.095 | ||||
| Diabetes mellitus | 0.704 | 0.890 | 0.486 | 1.627 | ||||
| Liver disease | 0.294 | 1.629 | 0.655 | 4.049 | ||||
| Obesity | 0.804 | 1.112 | 0.481 | 2.571 | ||||
| Renal impairment | <0.001 | 3.310 | 1.690 | 6.486 | 0.123 | 1.770 | 0.857 | 3.653 |
| Smoking history | 0.885 | 1.049 | 0.550 | 1.999 | ||||
| Neutrophils | ||||||||
| ≤ 500 | - | - | - | - | ||||
| 501 - 999 | 0.563 | 0.655 | 0.156 | 2.747 | ||||
| ≥ 1000 | 0.133 | 0.409 | 0.127 | 1.313 | ||||
| Lymphocytes | ||||||||
| ≤ 200 | – | – | – | – | ||||
| 201 - 499 | 0.127 | 5.009 | 0.634 | 39.609 | ||||
| ≥ 500 | 0.333 | 2.660 | 0.367 | 19.271 | ||||
| Time last chemotherapy | ||||||||
| In the last month | - | - | - | - | ||||
| In the last 3 months | 0.512 | 0.736 | 0.295 | 1.839 | ||||
| >3 months before COVID-19 | 0.608 | 0.832 | 0.411 | 1.683 | ||||
| Chemotherapy lines before COVID-19 | ||||||||
| 1 | - | - | - | - | ||||
| 2 | 0.063 | 1.739 | 0.971 | 3.114 | ||||
| 3 | 0.618 | 1.202 | 0.583 | 2.476 | ||||
| 4 | 0.082 | 2.398 | 0.894 | 6.432 | ||||
| >4 | 0.221 | 1.851 | 0.691 | 4.962 | ||||
| SARS-CoV-2 | ||||||||
| α mutation (Alpha) | - | - | - | - | ||||
| β mutation (Beta) | 0.853 | 1.140 | 0.285 | 4.563 | ||||
| Wild type | 0.684 | 0.750 | 0.187 | 3.000 | ||||
| Not tested/Unknown | 0.523 | 0.718 | 0.260 | 1.982 | ||||
| Vaccine doses before COVID-19 | ||||||||
| No vaccination | - | - | - | - | ||||
| One dose | 0.759 | 1.172 | 0.425 | 3.237 | ||||
| Two doses | 0.946 | 1.026 | 0.488 | 2.159 | ||||
| Three doses | 0.815 | 1.267 | 0.175 | 9.173 | ||||
| Time last vaccination to COVID-19 | ||||||||
| ≤14 days before COVID-19 | - | - | - | - | ||||
| >14 days before COVID-19 | 0.847 | 0.892 | 0.280 | 2.841 | ||||
| COVID-19 treatment | ||||||||
| No treatment | - | - | - | - | ||||
| Antivirals +/- corticosteroids +/- plasma | 0.510 | 1.736 | 0.337 | 8.950 | ||||
| Monoclonal antibodies +/- corticosteroids +/- plasma | 0.974 | 0.000 | 0.000 | . | ||||
| Antivirals + monoclonal antibodies +/- corticosteroids +/- plasma | 0.185 | 3.158 | 0.577 | 17.278 | ||||
| Corticosteroids | 0.033 | 4.983 | 1.139 | 21.810 | ||||
| Plasma +/- corticosteroids | 0.690 | 1.629 | 0.148 | 17.978 | ||||
| Unknown | 0.226 | 2.402 | 0.581 | 9.923 | ||||